# CRISPR Therapeutics AG (CRSP)

> Source: Nexqual · https://nexqual.com/CRSP · data as of 2026-10-28 20:00 UTC · cite as "Nexqual, CRISPR Therapeutics AG (CRSP), nexqual.com/CRSP" · informational, not investment advice.

**Price:** USD 54.11 (+5.13% on the day) · last close of Oct 28, 2026; US market closed, not a live price. Prev close 51.47 · day 50.1–54.17 · 52w 44.12–65.98 · market cap $5.23B · NGM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $13.4M, net income -$451M (-3368.7% margin), free cash flow -$371M (SEC filings).
- Insider open-market sales, last ~7 months: 8 Form 4 filings, $5.1M; 5 not under a Rule 10b5-1 plan ($3.6M); 0 by opportunistic insiders, 2 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.26 on a 1–5 scale) (23 analysts), mean target USD 85.63 (range 44–291).
- Total return with dividends: 1Y -13.5% vs S&P 500 +13.6%; 5Y -40.8% vs S&P 500 +79.8%.
- Next earnings: 2026-11-09, EPS estimate USD -1.06, revenue estimate $16.6M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $915M | $1.2M | $371M | $37.3M | $3.5M | $13.4M |
| Operating income | $374M | -$673M | -$223M | -$467M | -$665M | -$534M |
| Net income | $378M | -$650M | -$154M | -$366M | -$582M | -$451M |
| EPS (diluted) | $4.70 | -$8.36 | -$1.94 | -$4.34 | -$6.47 | — |
| Free cash flow | $457M | -$533M | -$270M | -$145M | -$346M | -$371M |
| Operating margin | 40.8% | -56190.4% | -60.0% | -1250.4% | -18933.6% | -3990.0% |
| Net margin | 41.3% | -54271.7% | -41.4% | -981.5% | -16569.8% | -3368.7% |
| Revenue growth | +127154.9% | -99.9% | +30885.5% | -89.9% | -90.6% | — |
| Cash + short-term investments | $2.38B | $1.82B | $1.69B | $1.90B | $1.98B | — |
| Total debt | — | — | — | — | $0K | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 390.7x · EV/Sales 257.9x · P/B 3.0x · FCF yield -7.10% · Earnings yield -8.62% · Net cash $1.78B · EV $3.45B

## Insider sales (SEC Form 4, open-market, last ~7 months)
3 of 8 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-19 | Kulkarni Samarth | Chief Executive Officer | 47,837 | $2.4M | 13.3% | No | Routine (sold in Feb & Mar each year 2023–2025; this trade is outside those months) |
| 2026-10-14 | George Simeon | Director | 14,514 | $720K | 0.7% | Yes (adopted December 12, 2025) | Too little history (no open-market trades in 2023 or 2024) |
| 2026-10-14 | Kasinger James R. | General Counsel and Secretary | 1,040 | $51K | 1.1% | No | Too little history (no open-market trades in 2023) |
| 2026-10-14 | Kulkarni Samarth | Chief Executive Officer | 4,098 | $202K | 1.6% | No | Routine (sold in Feb & Mar each year 2023–2025; this trade is outside those months) |
| 2026-10-06 | Kasinger James R. | General Counsel and Secretary | 1,990 | $119K | 2.1% | Yes (adopted May 6, 2026) | Too little history (no open-market trades in 2023) |
| 2026-09-22 | Kasinger James R. | General Counsel and Secretary | 10,400 | $626K | 9.9% | Yes (adopted May 6, 2026) | Too little history (no open-market trades in 2023) |
| 2026-09-17 | Behbahani Ali | Director | 13,679 | $781K | 45.1% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-29 | Patel Naimish | Chief Medical Officer | 3,786 | $211K | 16.4% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 2.26 on a 1–5 scale), 23 analysts; mean target USD 85.63 (low 44, high 291).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | UBS | Initiated | Neutral | $52 |
| 2026-08-31 | Citizens | Reiterated | Market Outperform | $80 |
| 2026-08-31 | Needham | Reiterated | Buy | $82 |
| 2026-08-25 | Citizens | Reiterated | Market Outperform | $80 |
| 2026-08-04 | Citigroup | Target raised | Buy | $82 → $88 |
| 2026-07-08 | HC Wainwright & Co. | Reiterated | Buy | $80 |
| 2026-07-06 | Citizens | Reiterated | Market Outperform | $80 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-29) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -13.5% | -40.8% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | -13.6% | -9.9% |
| Volatility (annualized) | 57.5% | 55.5% |
| Max drawdown | -30.7% (Oct 2025→Mar 2026) | -64.3% (Oct 2021→Mar 2025) |

## Peers (Biotechnology)
ORKA (Oruka Therapeutics, Inc.) USD 95.97 +0.17% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 91.97 -0.23% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.81 +1.58% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.9 +2.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.51 +0.92% · PRAX (Praxis Precision Medicines, Inc) USD 285.48 +6.69%

## More
Full page: https://nexqual.com/CRSP · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-1.06 | $-1.19 | +$0.13 | $16.6M | 17 |
| Next quarter (ends 2026-12-31) | $-1.16 | $-1.23 | +$0.07 | $17.4M | 17 |
| Current fiscal year (ends 2026-12-31) | $-4.45 | $-4.88 | +$0.43 | $40.4M | 19 |
| Next fiscal year (ends 2027-12-31) | $-3.55 | $-3.89 | +$0.33 | $154.0M | 19 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.94 | −$1.18 | Beat +20.3% | — |
| — | Quarter ended Mar 31, 2026 | −$1.28 | −$1.23 | Miss −4.1% | — |
| — | Quarter ended Dec 31, 2025 | −$1.37 | −$1.23 | Miss −11.4% | — |
| — | Quarter ended Sep 30, 2025 | −$1.17 | −$1.29 | Beat +9.3% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-10-19 | 8-K | Director or executive officer change, or pay arrangement — “a) Appointment of New Chief Financial Officer Appointment of Andrew J. Silver as Chief Financial Officer On October 19, 2026, CRISPR Therapeutics AG (the "Company") announced the promotion of Andrew J. Silver, currently the Company's SVP, Finance, to be the Company's Chief Financial Officer effective immediately. Mr. Silver will also serve as the Company's principal financial officer and principal accounting officer. Since January 2025, Mr. Silver, aged 42, has served as the Company's Senior Vice President of…” | https://www.sec.gov/Archives/edgar/data/1674416/000119312526425243/0001193125-26-425243-index.htm |
| 2026-08-14 | Schedule 13G/A | ORBIS INVESTMENT MANAGEMENT LTD, Allan Gray Australia Pty Ltd: 5.6% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1674416/000094059426000049/0000940594-26-000049-index.htm |
| 2026-08-03 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1674416/000119312526330672/0001193125-26-330672-index.htm |
| 2026-08-03 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1674416/000119312526330644/0001193125-26-330644-index.htm |
| 2026-07-27 | Schedule 13G/A | BlackRock, Inc.: 8.3% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1674416/000201238326002146/0002012383-26-002146-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.